Home » Partnership » Fellows » Alessia Gilardi

Alessia Gilardi

alessia-gilardiAlessia Gilardi was born in Cagliari, Italy, in 1986. After getting a Bachelor degree in Experimental Biology, she attended a Master in Molecular and Cellular Biology in the University of Cagliari, Italy.

As a master’s student, she focused on Molecular Virology and in particular for her thesis project, she worked on a screening for HIV-1 Reverse Transcriptase inhibitors. During that time, she participated also in an Erasmus exchange program and studied one semester at the University of Ulm, in Germany. During her stay, she worked on the characterization of Interferon-Inducible Transmembrane proteins as antiviral factors against HIV replication.

Currently, Alessia is a Marie Sklodowska-Curie Fellow within the ITN Translocation project at the Fraunhofer IME ScreeningPort, in Hamburg (Germany). Her research focuses on the identification of small molecules, which could act as adjuvants in antimicrobial therapies targeting gram-negative bacteria efflux pumps.

From this experience, she got the possibility to bridge the gap between computational and in vitro studies, gaining a range of expertise that spans from docking and high-throughput virtual screening to advanced biochemical and biophysical label-free technologies.

Furthermore, the extremely heterogeneous working environment and the several opportunities to collaborate with different research groups inside and outside the ITN Translocation network, contributed to improve her self-management, communication and interaction skills.

She is enrolled at the Jacobs University Bremen and she will receive her PhD in Biochemistry within the first trimester of 2017.

Contact: alessia.gilardi@ime.fraunhofer.de

LinkedIn page: https://de.linkedin.com/in/alessia-gilardi-34481182

Project web page: www.itn-translocation.eu

ITN Project: Novel approaches to identify small molecules modulating TolC protein function of E. coli  

Publications:

1. Biophysical characterization of E. coli TolC interaction with the known blocker hexaamminecobalt", A. Gilardi, S.P. Bhamidimarri, M. Broenstrup, U. Bilitewski, R.K.R. Marreddy, K.M. Pos, L. Benier, P. Gribbon, M.
Winterhalter, B. Windshuegel, BBA - General Subjects (2017), doi:10.1016/j.bbagen.2017.07.014